Multiple drugs in retreatment of chronic pulmonary tuberculosis. Results with capreomycin and ethambutol. 1968

A B Organick, and E M Wilson

UI MeSH Term Description Entries
D007612 Kanamycin Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components. Kanamycin A,Kanamycin Sulfate,Kantrex
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011718 Pyrazinamide A pyrazine that is used therapeutically as an antitubercular agent. Tisamid
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D004977 Ethambutol An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863) Dexambutol,EMB-Fatol,EMB-Hefa,Etambutol Llorente,Ethambutol Hydrochloride,Etibi,Miambutol,Myambutol,EMB Fatol,EMB Hefa,Hydrochloride, Ethambutol,Llorente, Etambutol
D005000 Ethionamide A second-line antitubercular agent that inhibits mycolic acid synthesis. Amidazine,Ethioniamide,Trecator,Trecator-SC,Trecator SC
D005260 Female Females

Related Publications

A B Organick, and E M Wilson
April 1966, Annals of the New York Academy of Sciences,
A B Organick, and E M Wilson
January 1970, Polish medical journal,
A B Organick, and E M Wilson
July 1969, Gruzlica i choroby pluc; tuberculosis et pneumonologia,
A B Organick, and E M Wilson
July 1971, Gruzlica i choroby pluc; tuberculosis et pneumonologia,
A B Organick, and E M Wilson
July 1973, Gruzlica i choroby pluc; tuberculosis et pneumonologia,
A B Organick, and E M Wilson
April 1970, British journal of diseases of the chest,
A B Organick, and E M Wilson
January 1973, Scandinavian journal of respiratory diseases,
A B Organick, and E M Wilson
January 1969, Acta tuberculosea et pneumologica Belgica,
A B Organick, and E M Wilson
April 1966, Annals of the New York Academy of Sciences,
A B Organick, and E M Wilson
January 1969, Beitrage zur Klinik und Erforschung der Tuberkulose und der Lungenkrankheiten,
Copied contents to your clipboard!